Anbio Biotechnology Limited
General Information | |
Business: | (Incorporated in the Cayman Islands)Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs. Our comprehensive range encompasses solutions for various applications, including over-the-counter (OTC) utilization, point-of-care (POCT) settings, and laboratory applications. By offering a versatile range of products, we ensure that healthcare providers and patients alike can access reliable and efficient diagnostic tools regardless of the healthcare setting. Our IVD products are designed to detect a wide range of biomarkers associated with critical medical domains. These domains encompass infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. By providing advanced diagnostic capabilities in these areas, we empower healthcare professionals to identify and monitor various conditions, facilitating timely intervention and patient care. Moreover, our IVD products are compatible with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, for both healthcare providers and patients. This flexibility allows for diagnostic testing across diverse patient populations and healthcare settings. Furthermore, the IVD assays we develop utilize established and widely used IVD technology platforms and their scientific principles to allow quick adoption by the healthcare providers and cost-efficient improvements to the already available products on the market. Anbio Biotechnology offers a comprehensive range of IVD products to meet the growing demand in the POCT setting and the OTC market. Currently, all of our IVD products are ready for commercialization and do not require additional development. Our local distribution partners in strategically selected countries cover countries in the EU, APAC, North and South Americas (collectively “Americas”), and Africa. Note: Net income and revenue are for the 12 months that ended June 30, 2024.(Note: Anbio Biotechnology Limited priced its IPO at $5.00 – the low end of its $5.00-to-$6.00 range – and sold all 1.6 million shares – the number in the prospectus – to raise $8.0 million on Tuesday night, Feb. 18, 2025.) |
Industry: | Diagnostic |
Employees: | 27 |
Founded: | 2021 |
Contact Information | |
Address | Wilhelm Gutbrod Str 21B, 60437, Frankfurt am Main, Germany |
Phone Number | +49 16 0962 47281 |
Web Address | https://www.anbio.com/ |
View Prospectus: | Anbio Biotechnology Limited |
Financial Information | |
Market Cap | $219.45mil |
Revenues | $9.53 mil (last 12 months) |
Net Income | $4.33 mil (last 12 months) |
IPO Profile | |
Symbol | NNNN |
Exchange | NASDAQ |
Shares (millions): | 1.6 |
Price range | $5.00 - $5.00 |
Est. $ Volume | $8.0 mil |
Manager / Joint Managers | AC Sunshine Securities |
CO-Managers | |
Expected To Trade: | 2/19/2025 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |